PAR · ALTHX.PA
THX Pharma
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
Loading market information…
PAR · ALINS.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:05 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Intrasense S.A.’s quoted price sits in the lower half of its reported 52-week range, 57.11% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Intrasense S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company's offerings feature the Myrian Imaging Layer, a versatile multi-modality visualization platform tailored for professionals in the health industry. It also provides Myrian Studio, a dedicated development environment empowering innovators, industrial partners, spin-offs, and research institutions to build medical imaging applications. Furthermore, Intrasense leverages its Myrian technologies to facilitate the creation of biomarkers and artificial intelligence solutions. A key component of its product line is Myrian Clinical Apps, an extensive collection of advanced post-processing clinical applications. This portfolio encompasses specialized modules like Myrian XP-Breast, XP-Prostate, XP-Liver, XP-Mammo, XP-Lung, XP-Colon, XP-Vessel, and XP-Cardiac, alongside Myrian XL-Onco for tracking lesions. These applications, which also provide solutions for analyzing specific pathologies or organs, offer various tools for interpreting data from MRI, CT scans, conventional radiology, and nuclear imaging examinations.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
€0.65+€0.02 (+3.67%)
Valbiotis S.A.’s quoted price sits in the lower half of its reported 52-week range, 50.08% below the high.
€5.55+€0.05 (+0.91%)
Euromedis Groupe’s quoted price sits in the upper half of its reported 52-week range, 9.76% below the high.
€0.85+€0.01 (+1.19%)
Biosynex S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.86% below the high.
€0.74+€0.07 (+10.45%)
Aelis Farma S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
€0.17+€0.01 (+6.46%)
Poxel S.A.’s quoted price sits in the lower half of its reported 52-week range, 64.29% below the high.
€0.10-€0.00 (-2.44%)
AMA Corporation Plc’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
€2.20€0.00 (0.0%)
Media Lab S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 45.0% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
